Background: Significant debate surrounds the issue of whether written consent is necessary for pragmatic randomized, controlled trials (RCTs) with low risk.
T
he learning health care system, which envisions research as a routinely integrated part of clinical practice, has the promise to improve the quality of patient care and reduce costs (1) . Such research would include pragmatic randomized, controlled trials (RCTs) evaluating standard-of-care interventions whose true comparative effectiveness is unknown (2) , and that may involve little added risk compared with normal clinical practice. Some commentators argue that written informed consent is therefore not ethically necessary and that it would make integration of research and clinical practice difficult because of the added cost, disruption of usual clinical practice, and selection bias (2, 3) . Instead, they argue that patients could receive regular notifications that the institution conducts pragmatic RCTs (4 -6) . However, critics respond that this approach is ethically inappropriate and may undermine public support for clinical research (7) . Recent draft guidance from the U.S. Office for Human Research Protections on what counts as "reasonably foreseeable risks" that must be disclosed to research participants has further complicated this debate (8) .
A recent survey by Cho and colleagues (9) found that most respondents wanted to be asked for permission to participate in pragmatic RCTs, although most would also accept verbal consent or general notification if written consent would make the research too difficult to conduct. However, the generalizability of these findings is uncertain because the study did not use a probability-based sample. Our survey used a nationally representative, probability-based sample to evaluate the views of the U.S. public on informed consent for pragmatic RCTs.
METHODS

Design Overview
We conducted a nationally representative online survey of the U.S. public between 12 December and 29 December 2014. Our survey assessed respondents' attitudes toward consent procedures in 2 scenarios of pragmatic trials. This study was reviewed and deemed exempt by the Office of Human Subjects Research Protection of the National Institutes of Health Clinical Center.
Setting and Participants
We used the GfK KnowledgePanel, a probabilitybased online panel of adults aged 18 years or older that is designed to be representative of the noninstitutionalized civilian U.S. population. The KnowledgePanel comprises about 55 000 active panel members recruited through a combination of probability-based, random-digit dialing and addressbased sampling to create a nationally representative panel covering 97% of households (10) . When recruited, households without Internet access receive a laptop and Internet service so that they can participate in online surveys. Panelists generally receive only nonSee also:
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survey-specific incentives through a points-based reward program amounting to approximately $4 to $6 per month. The panel has been shown to produce estimates similar to those derived from random-digit dialing telephone surveys (11, 12) . It is used by the National Science Foundation for its grant program involving general population experiments (13) and has been used to measure the public's preferences for informed consent in clinical and research settings (14 -17) .
Survey Development, Options, and Administration
To develop the survey, we conducted 2 pretesting sessions during meetings of the Empirical Research Laboratory in the Department of Bioethics of the National Institutes of Health, as well as 2 pilot surveys (n = 101) using Amazon's Mechanical Turk platform (an online, opt-in convenience sample) to ensure comprehension of the survey's content and obtain open-ended feedback. Use of the Mechanical Turk platform to conduct social science research has been described elsewhere (18 -20) . We found high levels of comprehension, with most respondents (88% to 100%) correctly answering 7 true/false questions about the scenario (on such topics as the seriousness of hypertension; similarities between the treatment options; whether the patient's treatment could be changed during the study, if necessary; and whether patients would be enrolled without being informed of the specific study under the general notification scenario). Finally, we revised our study on the basis of critical feedback from 2 anonymous peer reviewers for Time-sharing Experiments for the Social Sciences (TESS) (13) .
The survey (see the Supplement, available at www .annals.org) was designed to evaluate respondents' views on consent for pragmatic RCTs with low added risk compared with standard clinical care. Key elements of the survey are described in the Appendix Figure  ( available at www.annals.org). Panel members were randomly assigned to receive 1 of 2 research scenarios describing a pragmatic RCT. All respondents received a vignette describing a learning health care system that regularly integrates research as part of care provision. We then told respondents that hypertension treatment is an area of interest for such health care systems, given the high prevalence of the condition in the population and serious complications associated with uncontrolled hypertension. At this point, respondents received their respective research scenarios.
RCT Scenarios
The first scenario described a "drug RCT" comparing 2 commonly used first-line antihypertensives (both approved by the U.S. Food and Drug Administration) with similar adverse effects. The examples were based on the diuretics chlorthalidone and hydrochlorothiazide (6), although alternate drug names ("CTD" and "TRT") were used to prevent response bias among persons familiar with either drug.
The second scenario, intended to signal an even lower-risk study and a less intrusive-seeming research intervention to a lay audience, described a "dosetiming RCT," which tested the options of telling patients to take their once-daily antihypertensive in the morning versus at night. Respondents in this scenario were told that physicians generally do not tell patients when to take these medications. The research scenarios as provided to survey respondents are described in greater detail in the Appendix Figure. 
Consent Options
Respondents in each RCT scenario were then randomly assigned to either a choice between written informed consent and general notification or a choice between written informed consent and brief verbal consent (Appendix Figure) . The options were described as follows.
Written Consent. The written consent form would contain the 8 elements required by the Federal Common Rule (45 CFR §46) (21) . It was noted that this option would require extra time and effort from the clinic staff and the patient, making it difficult to integrate the research as part of usual care, and that, in some cases, the study would not be conducted.
General Notification. All patients would receive notifications (posters, brochures, and letters) that the health care system regularly conducts research, and eligible patients would be automatically enrolled in the study without being explicitly asked whether they would like to participate.
Verbal Consent. The patient's physician would briefly explain the study, emphasize that the treatment selection would be random, and record the patient's decision in the medical record.
EDITORS' NOTES Context
Experts debate whether written informed consent from participants is ethically necessary for pragmatic trials that evaluate standard care interventions with unknown comparative effectiveness.
Contribution
This national survey involving 2130 adults queried respondents about their support for written consent, verbal consent, or general notification for 2 research scenarios (a drug trial and a dose-timing trial). Most respondents (60% to 72%) recommended and preferred written informed consent for both scenarios.
Caution
The response rate was 64%.
Implication
Most of the public does not yet favor options other than obtaining written informed consent for participation in pragmatic trials.
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Survey Administration
Panel members were randomly assigned to the drug RCT or dose-timing RCT scenario when they were invited to participate in the survey; respondents were further randomly assigned to the alternative option (general notification or verbal consent) when they reached that part of the survey ( Figure 1 ). The randomizations were computer-generated and were concealed from respondents. Simple probability-based assignment was used for randomization, and neither stratification nor an imbalanced allocation scheme was used. To minimize missing data, respondents received a prompt if the primary outcome measures were left blank. Because the panel's policy is not to force respondents to answer specific questions, we decided a priori to exclude respondents who did not answer the questions on both primary outcome measures.
Outcome and Measurements
Two questions were used to evaluate which of the pairwise consent options respondents favored. First, we described a debate among members of the ethics review board over how to notify participants or obtain consent. The primary outcome measures were the respondent's recommendation to the ethics review board ("If you were to give advice to the ethics review board, would you recommend Written Consent or [General Notification/Verbal Consent]?") and the respondent's preference ("If you were a patient in this health care system, which would you personally prefer, Written Consent or [General Notification/Verbal Consent]?"). Responses to both questions were measured on a 4-point scale ("definitely" or "probably" for each response option).
In addition, respondents were asked to evaluate the study's value ("It is valuable to study whether one treatment option is more effective than the other for the treatment of high blood pressure"), risks to research participants ("Patients who participate in the randomized study face greater risks than patients who receive usual care"), and benefits to research participants ("Patients who participate in the randomized study are more likely to improve (lower) their high blood pressure than patients who receive usual care"). A 7-point scale (1 = strongly disagree; 4 = neutral; 7 = strongly agree) was used for response options.
Statistical Analysis
We estimated that a sample size of 400 respondents in each group would provide 80% power to detect a 10% absolute difference for all baseline levels of support, assuming a 2-sided ␣ level of 0.05. 
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We dichotomized recommendations to the ethics review board and personal preferences as supportive of either written consent or the alternative approach. Logistic regression models were used to assess whether the research scenario and alternative consent/ notification option were associated with respondents' recommendations and personal preferences. The models included main effects for the research scenario (drug RCT vs. dose-timing RCT) and the alternative option (general notification vs. verbal consent), as well as the interaction of the 2 factors. The relationship between respondents' recommendations to the ethics review board and their personal preferences was evaluated using conditional logistic regression. The effect of the research scenario on respondents' perceptions of the study's value, risk, and benefit was assessed using ordered logistic regression. To assess the association between respondents' perceptions of the study's risk and support for the alternative option, we used the Pearson chi-square test of independence corrected for the survey design.
All analyses were conducted in Stata, version 11.2 (StataCorp), using survey commands with poststratification weights provided by GfK to account for survey nonresponse and noncoverage. Statistical significance was defined as a P value less than 0.05, and all tests were 2-sided.
Role of the Funding Source
This study was supported in part by the Intramural Research Program of the National Institutes of Health Clinical Center. Funding for data collection and survey administration was provided by TESS. The funding sources had no role in the design of the study; analysis or interpretation of the data; preparation, review, or approval of the manuscript; or the decision to submit the manuscript for publication.
RESULTS
Respondent Characteristics
The survey was sent to 3330 panel members; 2302 respondents started the survey, and 2144 completed it. After exclusion of 14 persons for nonresponses to both primary outcome items, our final analysis included 2130 respondents (64.0% response rate) (Figure 1) . Respondents were older (median age, 51 vs. 47 years) and more commonly identified as non-Hispanic white (74.5% vs. 65.5%) before poststratification weights were applied versus after.
A diagnosis of hypertension was reported by 25.3% (585 of 2054) of respondents, and 21.3% (501 of 2054) reported using prescription medications for the condition. These findings are similar to the national prevalence and treatment rates for hypertension (22) . Respondent characteristics are shown in Table 1 .
Recommendations to the Ethics Review Board
Overall, 64.4% (95% CI, 62.2% to 66.6%) of respondents would definitely or probably recommend that the ethics committee use traditional written informed consent (Figure 2 [top] and Appendix Across all groups, 67.4% (CI, 65.3% to 69.5%) of respondents would prefer written informed consent if they were a patient in the health care system (Figure 2 [bottom] and Appendix Table 1 ). Figure 3 shows respondents' support for the alternative option in their recommendations to the ethics review board and personal preferences for each group. Responses to the 2 items were consistent across groups, with most (86.8% to 92.5%) having the same recommendation and personal preference (Appendix Table 2 , available at www .annals.org). Only respondents in the dose-timing RCT scenario preferred general notification at a significantly lower rate than they recommended it to the ethics review board (32.7% vs. 39.7%; P = 0.001).
A logistic regression model was used to test the effect of the experimental design of the survey on recommendations for using the alternative consent/notification option over written consent. We found that the effect of the alternative option varied by RCT scenario (P = 0.003 for interaction) (Figure 3) . Respondents who received the dose-timing RCT scenario were more likely than those who received the drug RCT scenario to recommend general notification over written consent (39.7% vs. 28.5%; P = 0.001). Similarly, respondents in the drug RCT scenario were more likely to recommend the alternative option if they received the option of conducting the study with verbal consent rather than general notification (37.5% vs. 28.5%; P = 0.004).
Similar analysis for respondents' personal preferences found that those receiving the verbal consent option were more likely than those receiving the general notification option to prefer forgoing written consent (P = 0.023). The effects of the RCT scenario (P = 0.164) and the interaction between the scenario and the alternative consent/notification option (P = 0.123) on respondents' preferences were not significant.
Views of Research Scenarios
Large majorities (72.1% to 72.3%, depending on the scenario) agreed that it is valuable to conduct the research, with no differences in perception between the scenarios ( Table 2) . A minority (19.5% to 22.7%) agreed that RCT participants face greater risks than patients receiving usual care, with those in the drug RCT group more likely to view the research as being riskier than usual care (P = 0.043). Few (17.2% to 18.0%) believed that research participants would benefit more than those receiving usual care.
Relationship Between Risk Perception and Recommendations to the Ethics Review Board
Overall, respondents who agreed that study participants face greater risks than patients receiving usual RCT = randomized, controlled trial. * 3 respondents did not answer this question. † "More than once a week," "once a week," or "once or twice a month." ‡ "A few times a year" or "once a year or less." § Assessed on a 7-point scale ("extremely liberal" to "extremely conservative"). Eight respondents did not answer this question. ͉͉ 76 respondents did not answer this question.
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care were less likely to recommend the alternative option to written consent (27.7%) than those who were neutral (32.5%) or disagreed (43.1%). This relationship between risk perception and recommendation to the ethics review board was observed in each group (Appendix Table 3 , available at www.annals.org).
DISCUSSION
Pragmatic RCTs have significant potential to improve medical care. However, there is concern that mandating written informed consent may undermine this value and preclude some studies altogether (23, 24) . To address these concerns, some commentators have proposed waiving written consent for studies that pose low risk compared with standard clinical care (6, 7). Our study aimed to measure the public's support for this approach (5) .
The results suggest that most (range across all groups, 60.3% to 71.5%) of the public favors written informed consent over verbal consent and general notification, the most widely advocated alternatives. This finding is important given that most respondents believed that the RCTs were valuable to conduct (72.2%), recognized that participation did not confer additional personal benefits (or were neutral on the subject) (82.4%), and recognized that participation posed no additional risks (or were neutral) (78.9%). The last finding contradicts the claim that people "automatically" assume RCTs are riskier than standard clinical care (23) . Of note, a clear majority (62.5%) of those who recognized that the studies did not pose added risks nonetheless recommended written consent. We hypothesized that the dose-timing RCT scenario would be perceived as a more innocuous intervention for a lay audience and thus would garner more support for the alternative consent options. Although respondents were indeed more likely to recommend use of the alternative options in the dose-timing RCT scenario than in the drug RCT scenario (average of the 2 alternative options, 37.7% vs. 33.4%), the effect was small. We also hypothesized that respondents would favor verbal consent more often than general notification because it retains crucial elements of informed consent (such as informing patients about the study and asking for their consent for participation). However, this was true only in the drug RCT scenario (37.5% vs. 28.5%).
Although most respondents favored written consent, the fact that approximately one third would recommend the alternative approach to the ethics review board (range, 28.5% to 39.7%) and would prefer it as a potential patient-participant (range, 28.4% to 35.5%) is remarkable. For example, nearly 40% of those who received the dose-timing RCT scenario would recommend general notification without specific consent to the ethics review board as the better option. This might be an underestimate because the survey portrayed RCTs in a generic learning health care system rather than in the respondent's own health care system or physician's clinic. In addition, verbal consent would probably be used in conjunction with general notification in practice, which would result in a greater effect. Our findings are largely consistent with those of the recent study by Cho and colleagues (9) . In both studies, the public's support for comparative effectiveness research was high; however, most respondents preferred written consent before being enrolled in specific studies. Cho and colleagues found that about half of respondents preferred written consent, whereas we found that about two thirds did. This difference may be due to the earlier study providing additional options for respondents to choose from or framing the research as being conducted in the respondent's own health care system. It may also be due to higher selection bias in the non-probability-based sample used by Cho and colleagues.
Our study has several limitations. First, the response rate was 64.0%. Poststratification weights mitigate some aspects of nonresponse bias but cannot account for systematic differences between respondents and nonrespondents, such as levels of trust toward research or health care institutions. Second, respondents received only brief descriptions of the research scenarios and consent options. Third, framing effects could have impacted respondents' attitudes given that the issues examined in this survey have not received much public deliberation. For example, we presented written informed consent as a burdensome but feasible option and required a choice of preference for one option over another. Had we presented the choice as between conducting the RCTs with an alternative consent option or not being able to conduct the RCTs with written consent, the results probably would have differed, as Cho and colleagues found in their study (9) . In addition, the scenarios, especially the dose-timing RCT, were intentionally designed to signal low risk for the purpose of this survey. Such research scenarios are likely to be more complicated in reality. Finally, because we did not test support for general notification and verbal consent head-to-head within participants, our findings cannot be interpreted as a direct policy preference (or indifference) among the public for verbal consent or general notification.
Our findings have 2 potential policy implications. First, because most the public currently prefers studyspecific written informed consent, adoption of alternative consent options for pragmatic RCTs without extensive education would be premature and could undermine public support for this important research. Thus, at present, rather than bypassing written informed consent, considering ways to make such consent more efficient and less burdensome is important. In particular, formal written consent for pragmatic RCTs may be able to meet the federal regulatory requirements without being excessively long and timeintensive (25) . Second, a substantial minority of respondents viewed general notification or verbal consent as better options than written consent in certain situations. Further education and public discussion about risks involved in pragmatic trials of standard therapies may lead to greater acceptance of such alternatives.
